MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

United Therapeutics Corp

Closed

SectorHealthcare

587.58 1.74

Overview

Share price change

24h

Current

Min

584.8

Max

589.33

Key metrics

By Trading Economics

Income

26M

364M

Sales

-9.3M

790M

P/E

Sector Avg

20.781

63.808

Profit margin

46.102

Employees

1,400

EBITDA

61M

524M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+8.03% upside

Dividends

By Dow Jones

Next Earnings

29 kwi 2026

Market Stats

By TradingEconomics

Market Cap

3.9B

25B

Previous open

585.84

Previous close

587.58

News Sentiment

By Acuity

50%

50%

168 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 kwi 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 kwi 2026, 18:15 UTC

Major News Events

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 kwi 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 kwi 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 kwi 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 kwi 2026, 20:11 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 kwi 2026, 19:34 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

17 kwi 2026, 19:34 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 kwi 2026, 19:31 UTC

Market Talk
Major News Events

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 kwi 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 kwi 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 kwi 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 kwi 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 kwi 2026, 18:57 UTC

Major News Events

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 kwi 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 kwi 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB 2026 Rev Guidance Unchanged

17 kwi 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 kwi 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 kwi 2026, 18:14 UTC

Market Talk
Major News Events

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 kwi 2026, 18:00 UTC

Major News Events

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 kwi 2026, 18:00 UTC

Major News Events

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 kwi 2026, 17:31 UTC

Market Talk
Major News Events

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 kwi 2026, 17:26 UTC

Market Talk
Earnings

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

8.03% upside

12 Months Forecast

Average 635.62 USD  8.03%

High 705 USD

Low 519 USD

Based on 14 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

10

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

292.345 / 309.245Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

168 / 348 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat